Date: 2012-05-04
Type of information: Licensing agreement
Compound: kallikrein biomarkers and associated algorithm for the detection of prostate cancer
Company: OPKO Health (USA) International Health Technology (UK)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: prostate cancer
Details: OPKO Health has announced execution of a license agreement granting International Health Technology, Ltd the right to offer OPKO\'s novel panel of kallikrein biomarkers and associated algorithm for the detection of prostate cancer in a laboratory setting in the U.K. , Ireland , Sweden and Denmark . The OPKO panel represents the culmination of a decade of research by scientists in Europe and the U.S. and has been demonstrated in over 10,000 patients to predict the probability of cancer-positive biopsy in men suspect for prostate cancer. Studies have shown use of the panel could eliminate a significant amount of unnecessary prostate biopsies, demonstrating a reduction of over 50%. International Health Technology, through close cooperation with some of the largest private hospitals chains in the UK and abroad, has access to world class private facilities and specialists to provide testing services for corporate clients in the private sector. IHT specializes in launching new diagnostic technology in the private sector as part of a clinical service and as a distribution partner. IHT mainly focuses on the UK market, but is expanding within the European Union .
Financial terms:
Latest news:
